PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30991038-4 2019 RIF treatment significantly induced MDR1 protein and mRNA levels in phorbol 12-myristate 13-acetate-stimulated THP1 macrophages (p < 0.001 and 0.01, respectively). Tetradecanoylphorbol Acetate 68-99 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 21375937-4 2011 RESULTS: RT-PCR or Western blot showed that the expressions of MDR1 and P-gp were significantly higher in MCF-7Taxol cells exposed to PMA stimuli (both P0.05). Tetradecanoylphorbol Acetate 134-137 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 24362330-0 2014 Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models. Tetradecanoylphorbol Acetate 0-31 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 24362330-10 2014 In agreement with the above results, PMA dose-dependently reduced intracellular ATP level and stimulated P-gp ATPase activity in both Caco-2 and MDCKII-MDR1 cells. Tetradecanoylphorbol Acetate 37-40 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 24362330-12 2014 CONCLUSION: PMA significantly inhibited P-gp-mediated efflux of digoxin in both Caco-2 and MDCKII-MDR1 cell monolayers via PKC activation. Tetradecanoylphorbol Acetate 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 24008321-0 2013 Effect of phorbol 12-myristate 13-acetate on function and gene expression of P-glycoprotein in adriamycin-resistant K562/ADM cells. Tetradecanoylphorbol Acetate 10-41 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 21375937-4 2011 RESULTS: RT-PCR or Western blot showed that the expressions of MDR1 and P-gp were significantly higher in MCF-7Taxol cells exposed to PMA stimuli (both P0.05). Tetradecanoylphorbol Acetate 134-137 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 29911380-5 2017 Compared to the vehicle-treated group, PMA statistically decreased P-gp luciferase activity, mRNA expression and protein expression. Tetradecanoylphorbol Acetate 39-42 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 29911380-8 2017 In addition, knockdown of PKCalpha, NF-kappaB or PXR can significantly attenuate PMA-induced P-gp suppression. Tetradecanoylphorbol Acetate 81-84 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 26462574-4 2015 Treatment by the reference PKC activator phorbol 12-myristate 13-acetate (PMA) for 48h was shown to decrease mRNA expression of various sinusoidal transporters, including OATP1B1, OATP2B1, NTCP, OCT1 and MRP3, but to increase that of OATP1B3, whereas mRNA expression of canalicular transporters was transiently enhanced (MDR1), decreased (BSEP and MRP2) or unchanged (BCRP) in human hepatoma HepaRG cells. Tetradecanoylphorbol Acetate 41-72 ATP binding cassette subfamily B member 1 Homo sapiens 321-325 26462574-4 2015 Treatment by the reference PKC activator phorbol 12-myristate 13-acetate (PMA) for 48h was shown to decrease mRNA expression of various sinusoidal transporters, including OATP1B1, OATP2B1, NTCP, OCT1 and MRP3, but to increase that of OATP1B3, whereas mRNA expression of canalicular transporters was transiently enhanced (MDR1), decreased (BSEP and MRP2) or unchanged (BCRP) in human hepatoma HepaRG cells. Tetradecanoylphorbol Acetate 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 321-325 20185911-8 2010 RESULTS: DFO significantly reduced the intracellular iron level, and led to approximately 70% reduction of MDR1 mRNA, approximately 50% of reduction of H-Fn mRNA and approximately 30% reduction of P-gp protein in TPA-differentiated K562 cells. Tetradecanoylphorbol Acetate 213-216 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 12614568-9 2003 Using either the MDR1 or the GFP gene we could demonstrate enhanced expression when cells were pretreated with phorbol 12-myristate 13-acetate (PMA) at low concentrations. Tetradecanoylphorbol Acetate 111-142 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 15322230-6 2004 Treatment of multidrug-resistant cells with 12-O-tetradecanoylphorbol-13-acetate, a phorbol ester that increases the phosphorylation of P-glycoprotein through activation of protein kinase C, or substituting phosphorylation sites of P-glycoprotein by nonphosphorylatable residues did not affect the ubiquitination of the transporter. Tetradecanoylphorbol Acetate 44-80 ATP binding cassette subfamily B member 1 Homo sapiens 136-150 15322230-6 2004 Treatment of multidrug-resistant cells with 12-O-tetradecanoylphorbol-13-acetate, a phorbol ester that increases the phosphorylation of P-glycoprotein through activation of protein kinase C, or substituting phosphorylation sites of P-glycoprotein by nonphosphorylatable residues did not affect the ubiquitination of the transporter. Tetradecanoylphorbol Acetate 44-80 ATP binding cassette subfamily B member 1 Homo sapiens 232-246 12614568-9 2003 Using either the MDR1 or the GFP gene we could demonstrate enhanced expression when cells were pretreated with phorbol 12-myristate 13-acetate (PMA) at low concentrations. Tetradecanoylphorbol Acetate 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 11857424-5 2002 This cell line, K562/TPA, shows a non-P-glycoprotein-mediated multidrug-resistant phenotype. Tetradecanoylphorbol Acetate 21-24 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 11488907-9 2001 This finding suggests that TPA-inducible MDR1 transcription mediated through the TPA responsive factor early growth response 1 (EGR-1) in this region of the promoter may be due to activation of PKC-alpha. Tetradecanoylphorbol Acetate 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 11734301-3 2002 However, recent reports have clarified that early growth response 1 gene (Egr1) positively regulates MDR1 transcription, while Wilms" tumor suppressor gene (WT1) does negative regulation of MDR1 gene expression in 12-O-tetradecanoylphorbol-13-acetate treated K562 cells. Tetradecanoylphorbol Acetate 214-250 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 11488907-9 2001 This finding suggests that TPA-inducible MDR1 transcription mediated through the TPA responsive factor early growth response 1 (EGR-1) in this region of the promoter may be due to activation of PKC-alpha. Tetradecanoylphorbol Acetate 81-84 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 10523856-11 1999 However, under identical conditions, MDR1 induction by TPA was completely unaffected by PD 098059. Tetradecanoylphorbol Acetate 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 11426620-4 2000 However, we show here that cytosine beta-D-arabinofuranoside (Ara C) and 12-O-tetradecanoylphorbol 13-acetate (TPA), agents that activated the MDR1 gene in the H9 T-cell leukemia line, caused different effects on PKC. Tetradecanoylphorbol Acetate 73-109 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 11426620-4 2000 However, we show here that cytosine beta-D-arabinofuranoside (Ara C) and 12-O-tetradecanoylphorbol 13-acetate (TPA), agents that activated the MDR1 gene in the H9 T-cell leukemia line, caused different effects on PKC. Tetradecanoylphorbol Acetate 111-114 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 11426620-6 2000 Furthermore, cell permeable ceramide, a lipid messenger known to mediate cellular effects of chemotherapeutic drugs and TPA, activated the MDR1 gene and down-regulated PKC. Tetradecanoylphorbol Acetate 120-123 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 10860921-6 2000 Thus, in K562 cells, 12-O-tetradecanoylphorbol-13-acetate-inducible expression of P-glycoprotein, the product of MDR1 gene, was strongly and selectively inhibited by the presence of a repressor protein targeted to the MDR1 promoter. Tetradecanoylphorbol Acetate 21-57 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 10860921-6 2000 Thus, in K562 cells, 12-O-tetradecanoylphorbol-13-acetate-inducible expression of P-glycoprotein, the product of MDR1 gene, was strongly and selectively inhibited by the presence of a repressor protein targeted to the MDR1 promoter. Tetradecanoylphorbol Acetate 21-57 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 10860921-6 2000 Thus, in K562 cells, 12-O-tetradecanoylphorbol-13-acetate-inducible expression of P-glycoprotein, the product of MDR1 gene, was strongly and selectively inhibited by the presence of a repressor protein targeted to the MDR1 promoter. Tetradecanoylphorbol Acetate 21-57 ATP binding cassette subfamily B member 1 Homo sapiens 218-222 10523856-1 1999 The MDR1 gene encoding the multidrug pump P-glycoprotein is transcriptionally activated in response to diverse extracellular stimuli, including the tumor promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 179-215 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10523856-1 1999 The MDR1 gene encoding the multidrug pump P-glycoprotein is transcriptionally activated in response to diverse extracellular stimuli, including the tumor promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 217-220 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10523856-3 1999 Downstream of protein kinase C (PKC), the effects of TPA are often mediated by the Raf-1/MEK/ERK mitogen-activated protein kinase (MAPK) cascade, and Raf-1 has been implicated in MDR1 induction by serum and mitogens. Tetradecanoylphorbol Acetate 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 179-183 10523856-4 1999 Therefore, we examined the potential role of MAPK activation in TPA-mediated MDR1 induction in human leukemia K562 cells. Tetradecanoylphorbol Acetate 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 10523856-5 1999 MDR1 mRNA expression was significantly increased by TPA in the concentration range of 4 - 100 nM, with a maximal response 5 - 10 h after TPA addition. Tetradecanoylphorbol Acetate 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 10523856-5 1999 MDR1 mRNA expression was significantly increased by TPA in the concentration range of 4 - 100 nM, with a maximal response 5 - 10 h after TPA addition. Tetradecanoylphorbol Acetate 137-140 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 10523856-6 1999 TPA-mediated MDR1 induction was inhibited by several PKC inhibitors including staurosporine, H7 and calphostin C. Tetradecanoylphorbol Acetate 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 10523856-9 1999 In order to determine the potential role of MAPKs in MDR1 induction by TPA, specific inhibitors were utilized. Tetradecanoylphorbol Acetate 71-74 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 10523856-13 1999 These data demonstrate that MDR1 induction by TPA occurs via a PKC-dependent mechanism that operates independently of ERK, p38 or JNK pathways, and thus have important implications for understanding the mechanisms of MDR1 induction by extracellular stimuli. Tetradecanoylphorbol Acetate 46-49 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 10523856-13 1999 These data demonstrate that MDR1 induction by TPA occurs via a PKC-dependent mechanism that operates independently of ERK, p38 or JNK pathways, and thus have important implications for understanding the mechanisms of MDR1 induction by extracellular stimuli. Tetradecanoylphorbol Acetate 46-49 ATP binding cassette subfamily B member 1 Homo sapiens 217-221 10392899-0 1999 The Wilms" tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Tetradecanoylphorbol Acetate 43-79 ATP binding cassette subfamily B member 1 Homo sapiens 98-120 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 26-62 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 26-62 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 26-62 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 10392899-3 1999 We have demonstrated that 12-O-tetradecanoylphorbol-13-acetate (TPA) increases transcription of the MDR1 gene and activates the MDR1 promoter, and that promoter activation by TPA requires binding of the zinc finger transcription factor EGR1 to specific MDR1 promoter sequences (C. McCoy and M. M. Cornwell, Mol. Tetradecanoylphorbol Acetate 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 10392899-6 1999 We demonstrate here that the Wilms" tumor (WT) suppressor, WT1, a member of the EGR family, inhibits the response of the MDR1 promoter to TPA in K562 cells. Tetradecanoylphorbol Acetate 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 10392899-7 1999 Inhibition is likely a direct effect of WT1 binding to the MDR1 promoter because: (a) WT1 expression does not inhibit the increase in EGR1 after TPA treatment; (b) inhibition by WT1 requires the zinc finger domain; (c) WT1 binds to MDR1 promoter sequences that bind EGR1 and are responsive to TPA; and (d) there is an inverse correlation between WT1 protein expression and MDR1 expression and promoter activity. Tetradecanoylphorbol Acetate 293-296 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 9751075-5 1998 These observations suggest that 12-O-tetradecanoylphorbol-13-acetate-induced P-gp phosphorylation may be associated with induction of P-gp-mediated drug efflux in the HTB-123 cell line. Tetradecanoylphorbol Acetate 32-68 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 9751075-5 1998 These observations suggest that 12-O-tetradecanoylphorbol-13-acetate-induced P-gp phosphorylation may be associated with induction of P-gp-mediated drug efflux in the HTB-123 cell line. Tetradecanoylphorbol Acetate 32-68 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 8687492-9 1996 H7 did not affect the basal level of P-glycoprotein in cells from control colonies or PMA-induced overexpression of P-glycoprotein in cells from PMA-treated colonies. Tetradecanoylphorbol Acetate 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 116-130 9353133-2 1997 Phorbol ester (PMA), added to stimulate phosphorylation of P-gp by protein kinase C (PKC), caused a decrease in the cellular accumulation of DNR and VP-16, both in multidrug-resistant (MDR) P-gp-overexpressing cells and in wild-type cells. Tetradecanoylphorbol Acetate 15-18 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 9353133-2 1997 Phorbol ester (PMA), added to stimulate phosphorylation of P-gp by protein kinase C (PKC), caused a decrease in the cellular accumulation of DNR and VP-16, both in multidrug-resistant (MDR) P-gp-overexpressing cells and in wild-type cells. Tetradecanoylphorbol Acetate 15-18 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 9353133-6 1997 Therefore, Cal-AM was used to study the effect of PMA-induced phosphorylation of P-gp on its transport activity. Tetradecanoylphorbol Acetate 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 9353133-11 1997 However, these studies provide evidence that PMA-induced PKC activity decreases cellular drug accumulation in a P-gp-independent manner. Tetradecanoylphorbol Acetate 45-48 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 9040943-3 1997 In this study, we investigated the physiological relevance of MDR1 gene regulation by NF-IL6 in response to PMA (phorbol 12-myristate 13-acetate)-induced differentiation. Tetradecanoylphorbol Acetate 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 9040943-3 1997 In this study, we investigated the physiological relevance of MDR1 gene regulation by NF-IL6 in response to PMA (phorbol 12-myristate 13-acetate)-induced differentiation. Tetradecanoylphorbol Acetate 113-144 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 8687492-13 1996 Differential effects of H7 on the PMA-induced changes suggest that different isoforms of PKC may be involved in cell growth and drug accumulation processes as well as P-glycoprotein expression. Tetradecanoylphorbol Acetate 34-37 ATP binding cassette subfamily B member 1 Homo sapiens 167-181 7565762-0 1995 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Tetradecanoylphorbol Acetate 0-36 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 7565762-3 1995 To identify cellular factors that regulate the expression of MDR1 in hematopoietic cells, we characterized the cis- and trans-acting factors mediating 12-O-tetradecanoylphorbol-13-acetate (TPA) activation of the MDR1 promoter in K562 cells. Tetradecanoylphorbol Acetate 151-187 ATP binding cassette subfamily B member 1 Homo sapiens 212-216 7565762-3 1995 To identify cellular factors that regulate the expression of MDR1 in hematopoietic cells, we characterized the cis- and trans-acting factors mediating 12-O-tetradecanoylphorbol-13-acetate (TPA) activation of the MDR1 promoter in K562 cells. Tetradecanoylphorbol Acetate 189-192 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 7565762-3 1995 To identify cellular factors that regulate the expression of MDR1 in hematopoietic cells, we characterized the cis- and trans-acting factors mediating 12-O-tetradecanoylphorbol-13-acetate (TPA) activation of the MDR1 promoter in K562 cells. Tetradecanoylphorbol Acetate 189-192 ATP binding cassette subfamily B member 1 Homo sapiens 212-216 7565762-4 1995 Transient-transfection assays demonstrated that an MDR1 promoter construct containing nucleotides -69 to +20 conferred a TPA response equal to that of a construct containing nucleotides -434 to +105. Tetradecanoylphorbol Acetate 121-124 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 7565762-5 1995 TPA induced EGR1 binding to the -69/+20 promoter sequences over a time course which correlated with increased MDR1 promoter activity and increased steady-state MDR1 RNA levels. Tetradecanoylphorbol Acetate 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 7565762-5 1995 TPA induced EGR1 binding to the -69/+20 promoter sequences over a time course which correlated with increased MDR1 promoter activity and increased steady-state MDR1 RNA levels. Tetradecanoylphorbol Acetate 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 160-164 7565762-8 1995 A mutation in this site that inhibited EGR protein binding blocked the -69/+20 MDR1 promoter response to TPA. Tetradecanoylphorbol Acetate 105-108 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 7646552-5 1995 TPA treatment caused an increase in P-glycoprotein, increased drug resistance and decreased rhodamine-123 accumulation which was verapamil sensitive, demonstrating that TPA induced a fully functional P-glycoprotein. Tetradecanoylphorbol Acetate 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 7646552-5 1995 TPA treatment caused an increase in P-glycoprotein, increased drug resistance and decreased rhodamine-123 accumulation which was verapamil sensitive, demonstrating that TPA induced a fully functional P-glycoprotein. Tetradecanoylphorbol Acetate 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 200-214 7646552-5 1995 TPA treatment caused an increase in P-glycoprotein, increased drug resistance and decreased rhodamine-123 accumulation which was verapamil sensitive, demonstrating that TPA induced a fully functional P-glycoprotein. Tetradecanoylphorbol Acetate 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 7646552-5 1995 TPA treatment caused an increase in P-glycoprotein, increased drug resistance and decreased rhodamine-123 accumulation which was verapamil sensitive, demonstrating that TPA induced a fully functional P-glycoprotein. Tetradecanoylphorbol Acetate 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 200-214 7690250-2 1993 In the present study, inhibition of protein kinase C with calphostin C or stauroporine or prolonged treatment with the phorbol ester TPA decreased phosphorylation of P-glycoprotein, and impaired transport of vinblastine. Tetradecanoylphorbol Acetate 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 7908894-2 1994 K562/TPA was found to be a non-P-glycoprotein-mediated multidrug-resistant cell line, in which intracellular drug accumulation was not reduced. Tetradecanoylphorbol Acetate 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 7628641-1 1995 We compared the influence of exogenous N-ras oncogene and treatment with PKC agonist 12-O-tetradecanoylphorbol-13-acetate (TPA) on P-glycoprotein (Pgp) function in various human, rat and dog cell lines. Tetradecanoylphorbol Acetate 85-121 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 7628641-1 1995 We compared the influence of exogenous N-ras oncogene and treatment with PKC agonist 12-O-tetradecanoylphorbol-13-acetate (TPA) on P-glycoprotein (Pgp) function in various human, rat and dog cell lines. Tetradecanoylphorbol Acetate 85-121 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 7628641-1 1995 We compared the influence of exogenous N-ras oncogene and treatment with PKC agonist 12-O-tetradecanoylphorbol-13-acetate (TPA) on P-glycoprotein (Pgp) function in various human, rat and dog cell lines. Tetradecanoylphorbol Acetate 123-126 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 7628641-1 1995 We compared the influence of exogenous N-ras oncogene and treatment with PKC agonist 12-O-tetradecanoylphorbol-13-acetate (TPA) on P-glycoprotein (Pgp) function in various human, rat and dog cell lines. Tetradecanoylphorbol Acetate 123-126 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 7949466-6 1994 Phorbol 12-myristate 13-acetate (PMA) increased the phosphorylation of P-glycoprotein 6-fold and selectively decreased the accumulation of vinblastine in resistant MCF-7/AdrR cells. Tetradecanoylphorbol Acetate 0-31 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 7949466-6 1994 Phorbol 12-myristate 13-acetate (PMA) increased the phosphorylation of P-glycoprotein 6-fold and selectively decreased the accumulation of vinblastine in resistant MCF-7/AdrR cells. Tetradecanoylphorbol Acetate 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 8105473-3 1993 Unglycosylated mdr1 retains the ability to bind the photoactivatable drug analog [125I]iodoarylazidoprazosin and confers resistance to tetraphenylphosphonium (TPP+) and tetraphenylarsonium (TPA+), known mdr1 substrates. Tetradecanoylphorbol Acetate 190-193 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 1360276-5 1992 We have studied the effects of lymphocyte-activating agents on P-glycoprotein activity in normal human lymphocytes, and found that 12-O-tetradecanoylphorbol-13-acetate (TPA), an efficient agonist of PKC, increased the activity as well as the levels of P-glycoprotein in these cells. Tetradecanoylphorbol Acetate 131-167 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 1377325-4 1992 In 32P-labeled intact KB-V1 cells, P-glycoprotein phosphorylation was stimulated by both 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of PKC, and okadaic acid. Tetradecanoylphorbol Acetate 89-125 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 1377325-4 1992 In 32P-labeled intact KB-V1 cells, P-glycoprotein phosphorylation was stimulated by both 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of PKC, and okadaic acid. Tetradecanoylphorbol Acetate 127-130 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 8093247-9 1993 Phosphorylation of P-glycoprotein, the cellular mediator of the MDR phenotype, was increased > 20-fold in the unstimulated MCF-7-MDR cell line and its phosphorylation was further increased 2-fold in response to phorbol 12-myristate 13-acetate. Tetradecanoylphorbol Acetate 214-245 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 1360276-5 1992 We have studied the effects of lymphocyte-activating agents on P-glycoprotein activity in normal human lymphocytes, and found that 12-O-tetradecanoylphorbol-13-acetate (TPA), an efficient agonist of PKC, increased the activity as well as the levels of P-glycoprotein in these cells. Tetradecanoylphorbol Acetate 131-167 ATP binding cassette subfamily B member 1 Homo sapiens 252-266 1360276-5 1992 We have studied the effects of lymphocyte-activating agents on P-glycoprotein activity in normal human lymphocytes, and found that 12-O-tetradecanoylphorbol-13-acetate (TPA), an efficient agonist of PKC, increased the activity as well as the levels of P-glycoprotein in these cells. Tetradecanoylphorbol Acetate 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 1360276-5 1992 We have studied the effects of lymphocyte-activating agents on P-glycoprotein activity in normal human lymphocytes, and found that 12-O-tetradecanoylphorbol-13-acetate (TPA), an efficient agonist of PKC, increased the activity as well as the levels of P-glycoprotein in these cells. Tetradecanoylphorbol Acetate 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 252-266 1360276-6 1992 TPA also increased P-glycoprotein expression in several cell lines derived from different types of leukemias and solid tumors. Tetradecanoylphorbol Acetate 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 1360276-8 1992 Induction of MDR1 mRNA was apparent as early as two hours after the addition of TPA. Tetradecanoylphorbol Acetate 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 1360276-10 1992 The induction of MDR1 expression by TPA and DAG was suppressed by staurosporine, a protein kinase inhibitor. Tetradecanoylphorbol Acetate 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 1972016-1 1990 Treatment of drug-resistant human KB carcinoma cells (KB-V1) with 0.2 microM phorbol 12-myristate 13-acetate (PMA) resulted in increases of 4-fold in both membrane-associated protein kinase C activity and phosphorylation of P-glycoprotein. Tetradecanoylphorbol Acetate 77-108 ATP binding cassette subfamily B member 1 Homo sapiens 224-238 1972016-1 1990 Treatment of drug-resistant human KB carcinoma cells (KB-V1) with 0.2 microM phorbol 12-myristate 13-acetate (PMA) resulted in increases of 4-fold in both membrane-associated protein kinase C activity and phosphorylation of P-glycoprotein. Tetradecanoylphorbol Acetate 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 224-238